Chardan Capital Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $28.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 58.64% from the company’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Oculis in a report on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $28.80.

Oculis Stock Up 0.5 %

OCS stock opened at $17.65 on Tuesday. The stock’s 50 day moving average is $16.33 and its 200-day moving average is $13.79. Oculis has a twelve month low of $10.50 and a twelve month high of $18.10. The firm has a market capitalization of $714.90 million, a PE ratio of -9.15 and a beta of -0.33. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.